Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib Intensification Early After AHCT for Plasma Cell Myeloma
NCT01658904Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2012
- Primary completion
- Feb 2014
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by National Cancer Institute. Started Jul 2012; status: terminated.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01658904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658904.